,2 However, substantial clinical and biological heterogeneity exists in HER2-positive disease, which affects patients' prognosis and treatment benefit.2, 3, 4, 5 Thus, strategies to optimize therapy and improve quality of life have been recently explored for patients with early-stage HER2-positive breast cancer. Here, ERBB2 is linked to breast carcinoma.